Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium – an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879 - Quinn, David I.; Tsao-Wei, Denice D.; Twardowski, Przemyslaw; Aparicio, Ana M.; Frankel, Paul; Chatta, Gurkamal; Wright, John J.; Groshen, Susan G.; Khoo, Stella; Lenz, Heinz-Josef; Lara, Primo N.; Gandara, David R.; et al. (Investigational new drugs, 2021)
Keywords: Adult; Aged; Aged, 80 and over; Anticancer properties; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antitumor activity; Apoptosis; Bladder; Bladder cancer; Cancer; Carcinoma, Transitional Cell - drug therapy; Carcinoma, Transitional Cell - mortality; Carcinoma, Transitional Cell - pathology; Computed tomography; Consortia; Cytopenia; Dosage; Female; Histone deacetylase; Histone Deacetylase Inhibitors - administration & dosage; Histone Deacetylase Inhibitors - adverse effects; Histones; Humans; Hydroxamic acid; Inhibitors; Kaplan-Meier Estimate; Lymphocytes; Lymphocytes T; Magnetic resonance imaging; Male; Medical imaging; Medicine; Medicine & Public Health; Metastases; Metastasis; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - mortality; Neoplasm Recurrence, Local - pathology; Oncology; Pharmacology/Toxicology; Phase II Studies; Platinum; Schedules; Survival; Therapy; Toxicity; Transitional cell carcinoma; Treatment Outcome; Tumor cell lines; Urologic Neoplasms - drug therapy; Urologic Neoplasms - mortality; Urologic Neoplasms - pathology; Urothelial cancer; Urothelium; Urothelium - pathology; Vorinostat - administration & dosage; Vorinostat - adverse effects; Urothelial cancer; Clinical trial; Histone deacetylase inhibitor; Bladder cancer